ARGENX SE-ADR (NASDAQ:ARGX) Downgraded by Zacks Investment Research

ARGENX SE-ADR (NASDAQ:ARGX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, October 25th.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

Separately, Cowen and Company restated a “buy” rating on shares of ARGENX SE-ADR in a research report on Thursday, August 24th.

ARGENX SE-ADR (NASDAQ:ARGX) traded up $1.43 during midday trading on Wednesday, reaching $24.15. 17,300 shares of the company’s stock traded hands, compared to its average volume of 28,542. ARGENX SE-ADR has a 1 year low of $17.33 and a 1 year high of $27.25.

TRADEMARK VIOLATION NOTICE: “ARGENX SE-ADR (NASDAQ:ARGX) Downgraded by Zacks Investment Research” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/11/zacks-investment-research-downgrades-argenx-se-adr-argx-to-hold.html.

Several institutional investors have recently bought and sold shares of ARGX. FMR LLC bought a new position in shares of ARGENX SE-ADR in the second quarter valued at approximately $15,990,000. VHCP Management II LLC bought a new position in shares of ARGENX SE-ADR in the second quarter valued at approximately $13,615,000. Pictet Asset Management Ltd. bought a new position in shares of ARGENX SE-ADR in the third quarter valued at approximately $11,812,000. Federated Investors Inc. PA bought a new position in shares of ARGENX SE-ADR in the second quarter valued at approximately $9,545,000. Finally, Franklin Resources Inc. bought a new position in shares of ARGENX SE-ADR in the second quarter valued at approximately $7,424,000. Institutional investors and hedge funds own 24.70% of the company’s stock.

About ARGENX SE-ADR

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply